Login to Your Account



No Longer Off-Label, Amgen's Enbrel Wins Psoriasis Approval

By Randall Osborne


Tuesday, May 4, 2004
Already used off-label for psoriasis - and approved for rheumatoid arthritis and psoriatic arthritis - Amgen Inc.'s Enbrel (etanercept) won FDA approval for treating those with moderate to severe forms of the skin condition who are candidates for systemic therapy or phototherapy. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription